Acadia Healthcare Reports Strong Third Quarter 2024 Results
Acadia Healthcare reported strong Q3 2024 results with revenue of $815.6 million, up 8.7% year-over-year. Same facility revenue increased 8.6%, driven by a 3.6% increase in revenue per patient day and 4.7% growth in patient days. Net income reached $68.1 million ($0.74 per share), while adjusted income was $84.1 million ($0.91 per share). Adjusted EBITDA grew 10.5% to $194.3 million. The company expanded its facilities, adding 15 beds and five new CTCs during Q3, now operating 164 CTCs across 32 states. Acadia updated its 2024 guidance, projecting revenue of $3.15-3.165 billion and adjusted EBITDA of $725-735 million.
Acadia Healthcare ha riportato risultati solidi per il terzo trimestre del 2024, con un fatturato di 815,6 milioni di dollari, in aumento dell'8,7% rispetto all'anno precedente. I ricavi della stessa struttura sono aumentati dell'8,6%, grazie a un incremento del 3,6% dei ricavi per giorno paziente e un aumento del 4,7% nei giorni di degenza. L'utile netto ha raggiunto 68,1 milioni di dollari (0,74 dollari per azione), mentre l'utile rettificato è stato di 84,1 milioni di dollari (0,91 dollari per azione). L'EBITDA rettificato è aumentato del 10,5% raggiungendo 194,3 milioni di dollari. L'azienda ha ampliato le sue strutture, aggiungendo 15 letti e cinque nuovi CTC durante il terzo trimestre, ora operando con 164 CTC in 32 stati. Acadia ha aggiornato le sue previsioni per il 2024, stimando un fatturato tra 3,15 e 3,165 miliardi di dollari e un EBITDA rettificato tra 725 e 735 milioni di dollari.
Acadia Healthcare informó resultados sólidos para el tercer trimestre de 2024, con ingresos de 815.6 millones de dólares, un aumento del 8.7% en comparación con el año anterior. Los ingresos de las mismas instalaciones aumentaron un 8.6%, impulsados por un incremento del 3.6% en los ingresos por día de paciente y un crecimiento del 4.7% en días de pacientes. El ingreso neto alcanzó 68.1 millones de dólares (0.74 dólares por acción), mientras que el ingreso ajustado fue de 84.1 millones de dólares (0.91 dólares por acción). El EBITDA ajustado creció un 10.5% hasta 194.3 millones de dólares. La compañía amplió sus instalaciones, agregando 15 camas y cinco nuevos CTC durante el tercer trimestre, ahora operando 164 CTC en 32 estados. Acadia actualizó su pronóstico para 2024, proyectando ingresos de 3.15 a 3.165 mil millones de dólares y un EBITDA ajustado de 725 a 735 millones de dólares.
Acadia Healthcare는 2024년 3분기 강력한 실적을 보고하며, 수익은 8억 1560만 달러로, 전년 대비 8.7% 증가했습니다. 동일 시설 수익은 8.6% 증가했으며, 이는 환자 하루당 수익의 3.6% 증가와 환자 수일의 4.7% 증가에 힘입은 것입니다. 순이익은 6810만 달러 (주당 0.74 달러)에 도달했으며, 조정된 소득은 8410만 달러 (주당 0.91 달러)였습니다. 조정 EBITDA는 10.5% 증가하여 1억 9430만 달러에 이르렀습니다. 이 회사는 3분기 동안 15개의 침대와 5개의 새로운 CTC를 추가하여 시설을 확장했으며, 현재 32개 주에서 164개의 CTC를 운영하고 있습니다. Acadia는 2024년 예상치를 업데이트하며, 31.5억에서 31.65억 달러의 수익과 7.25억에서 7.35억 달러의 조정 EBITDA를 예상하고 있습니다.
Acadia Healthcare a annoncé de solides résultats pour le troisième trimestre 2024, avec un chiffre d'affaires de 815,6 millions de dollars, en hausse de 8,7 % par rapport à l'année précédente. Les revenus des mêmes installations ont augmenté de 8,6 %, soutenus par une augmentation de 3,6 % des revenus par jour de patient et une croissance de 4,7 % des jours de patient. Le revenu net a atteint 68,1 millions de dollars (0,74 dollar par action), tandis que le revenu ajusté s'est élevé à 84,1 millions de dollars (0,91 dollar par action). L'EBITDA ajusté a augmenté de 10,5 % pour atteindre 194,3 millions de dollars. L'entreprise a élargi ses installations en ajoutant 15 lits et cinq nouveaux CTC au cours du troisième trimestre, opérant désormais 164 CTC dans 32 États. Acadia a mis à jour ses prévisions pour 2024, projetant un chiffre d'affaires de 3,15 à 3,165 milliards de dollars et un EBITDA ajusté de 725 à 735 millions de dollars.
Acadia Healthcare berichtete über starke Ergebnisse im 3. Quartal 2024 mit einem Umsatz von 815,6 Millionen Dollar, was einem Anstieg von 8,7 % im Jahresvergleich entspricht. Der Umsatz der gleichen Einrichtung stieg um 8,6 %, was auf einen Anstieg von 3,6 % der Einnahmen pro Patienten-Tag und einem Wachstum von 4,7 % bei Patiententagen zurückzuführen ist. Der Nettogewinn erreichte 68,1 Millionen Dollar (0,74 Dollar pro Aktie), während das bereinigte Einkommen 84,1 Millionen Dollar (0,91 Dollar pro Aktie) betrug. Das bereinigte EBITDA wuchs um 10,5 % auf 194,3 Millionen Dollar. Das Unternehmen hat seine Einrichtungen erweitert, indem es im dritten Quartal 15 Betten und fünf neue CTCs hinzugefügt hat, und betreibt nun 164 CTCs in 32 Staaten. Acadia hat seine Prognose für 2024 aktualisiert und rechnet mit einem Umsatz von 3,15 bis 3,165 Milliarden Dollar und einem bereinigten EBITDA von 725 bis 735 Millionen Dollar.
- Revenue growth of 8.7% YoY to $815.6 million
- Same facility revenue increased 8.6%
- Adjusted EBITDA grew 10.5% to $194.3 million
- Same facility adjusted EBITDA margin improved 100 bps to 29.7%
- Strong expansion with 15 new beds and 5 new CTCs in Q3
- Healthy financial position with net leverage ratio of 2.5x
- Closure of two facilities during Q3 2024
- Reduced guidance due to facility closures ($17M revenue impact)
Insights
Acadia Healthcare delivered a robust Q3 2024 performance with notable growth metrics. Revenue increased by
The expansion strategy remains on track with 15 new beds added to existing facilities and 5 new CTCs launched in Q3. With a healthy balance sheet showing a net leverage ratio of 2.5x and
The expansion of Acadia's treatment network demonstrates strong market positioning in behavioral healthcare. Operating 164 CTCs across 32 states serving 72,000 daily patients shows significant scale advantages. The strategic joint venture partnerships with major health systems like Henry Ford Health and Intermountain Health enhance market penetration and credibility.
The planned addition of approximately 1,200 beds, with 1,000 expected to be licensed by year-end, indicates substantial capacity growth. The
Provides Updated Guidance for 2024
Third Quarter Highlights
-
Revenue totaled
, an increase of$815.6 million 8.7% over the third quarter of 2023 -
Same facility revenue increased
8.6% compared with the third quarter of 2023, including an increase in revenue per patient day of3.6% and an increase in patient days of4.7% -
Net income attributable to Acadia totaled
, or$68.1 million per diluted share$0.74 -
Adjusted income attributable to Acadia totaled
, or$84.1 million per diluted share$0.91 -
Adjusted EBITDA totaled
, an increase of$194.3 million 10.5% over the third quarter of 2023, excluding provider relief funds -
Same facility adjusted EBITDA margin increased 100 bps to
29.7% over the third quarter of 2023
Adjusted income attributable to Acadia and Adjusted EBITDA are non-GAAP financial measures. A reconciliation of all non-GAAP financial measures in this press release begins on page 8.
Third Quarter Results
Chris Hunter, Chief Executive Officer of Acadia Healthcare Company, remarked, “Our financial results for the third quarter of 2024 reflect continued execution of our growth strategy. We have the scale and expertise to support patients across the continuum of care. We are proud of the important work we are doing and are committed to providing safe, quality care for the patients, families and communities we serve while creating long-term value for our stockholders.”
Strategic Investments for Long-Term Growth
During the third quarter of 2024, the Company continued to make progress in meeting its strategic growth objectives. This includes the addition of 15 beds to existing facilities and the addition of five new CTCs during the quarter. With these additions, Acadia now operates 164 CTCs across 32 states treating over 72,000 patients daily and remains on track to open up to 14 new CTCs for the full year.
In the first nine months of the year, the Company opened 79 new beds at existing facilities. For the full year, the Company expects to open over 400 new beds at existing facilities, including over 300 beds expected in the fourth quarter.
In the first nine months of the year, the Company also opened two new facilities, totaling 120 beds. The Company remains on pace to complete construction on several additional new wholly owned and joint venture facilities, totaling nearly 700 new beds in the fourth quarter, including joint venture hospitals in partnership with Henry Ford Health in
Acadia has 21 joint venture partnerships for 22 hospitals, with 11 hospitals already in operation and 11 additional hospitals expected to open in the coming years.
Cash and Liquidity
Maintaining a strong financial position to support growth investments and disciplined capital allocation are top priorities for Acadia. As of September 30, 2024, the Company had
Net leverage ratio is a non-GAAP financial measure. A reconciliation of all non-GAAP financial measures in this press release begins on page 8.
2024 Financial Guidance
Acadia today revised its previously announced financial guidance for 2024. Revised guidance reflects the closure of two facilities during the third quarter(2).
|
2024 Guidance Range |
|||||
Revenue(1) |
|
|
|
|
|
|
Adjusted EBITDA(1) |
|
|
|
|
|
|
Adjusted earnings per diluted share(1) |
|
|
|
|
|
|
Interest expense |
|
|
|
|
|
|
Tax rate |
|
|
|
|
|
|
Depreciation and amortization expense |
|
|
|
|
|
|
Stock compensation expense |
|
|
|
|
|
|
Operating cash flows |
|
|
|
|
|
|
Expansion capital expenditures |
|
|
|
|
|
|
Maintenance and IT capital expenditures |
|
|
|
|
|
|
Total bed additions, excluding acquisitions(3) |
|
|
|
|
|
Approx. 1,200 beds |
|
|
(1) |
Includes one-time state payments of approximately |
|
(2) |
Prior full-year guidance assumed approximately |
|
(3) |
Company anticipates completing construction on approximately 1,200 beds, of which approximately 1,000 are expected to be licensed and available to serve patients by year end, with the remaining beds expected to receive licensure in the first quarter. The exact number of beds available to serve patients at year end will depend on timing of anticipated required licenses. |
|
The Company’s guidance does not include the impact of any future acquisitions, divestitures, transaction, legal and other costs or non-recurring legal settlements expense.
Conference Call
Acadia will hold a conference call to discuss its third quarter financial results at 8:00 a.m. Central Time/9:00 a.m. Eastern Time on Thursday, October 31, 2024. A live webcast of the conference call will be available at www.acadiahealthcare.com in the “Investors” section of the website. The webcast of the conference call will be available for 30 days.
About Acadia
Acadia is a leading provider of behavioral healthcare services across
Forward-Looking Information
This press release contains forward-looking statements. Generally, words such as “may,” “will,” “should,” “could,” “anticipate,” “expect,” “intend,” “estimate,” “plan,” “continue,” and “believe” or the negative of or other variation on these and other similar expressions identify forward-looking statements. These forward-looking statements are made only as of the date of this press release. We do not undertake to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are based on current expectations and involve risks and uncertainties and our future results could differ significantly from those expressed or implied by our forward-looking statements. Factors that may cause actual results to differ materially include, without limitation, (i) potential difficulties in successfully integrating the operations of acquired facilities or realizing the expected benefits and synergies of our facility expansions, acquisitions, joint ventures and de novo transactions; (ii) Acadia’s ability to add beds, expand services, enhance marketing programs and improve efficiencies at its facilities; (iii) potential reductions in payments received by Acadia from government and commercial payors; (iv) the occurrence of patient incidents, governmental investigations, litigation and adverse regulatory actions, which could adversely affect the price of our common stock and result in substantial payments and incremental regulatory burdens; (v) the risk that Acadia may not generate sufficient cash from operations to service its debt and meet its working capital and capital expenditure requirements; (vi) potential disruptions to our information technology systems or a cybersecurity incident; and (vii) potential operating difficulties, including, without limitation, disruption to the
Acadia Healthcare Company, Inc. |
||||||||||||||||
Condensed Consolidated Statements of Operations |
||||||||||||||||
(Unaudited) |
||||||||||||||||
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
||||||||||||||
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
||
(In thousands, except per share amounts) |
||||||||||||||||
Revenue | $ |
815,634 |
|
$ |
750,334 |
|
$ |
2,379,725 |
|
$ |
2,185,938 |
|
||||
Salaries, wages and benefits (including equity-based compensation expense of |
|
428,147 |
|
|
394,150 |
|
|
1,265,427 |
|
|
1,171,960 |
|
||||
Professional fees |
|
48,498 |
|
|
45,540 |
|
|
142,236 |
|
|
130,468 |
|
||||
Supplies |
|
29,623 |
|
|
27,147 |
|
|
84,153 |
|
|
79,312 |
|
||||
Rents and leases |
|
12,389 |
|
|
11,731 |
|
|
36,141 |
|
|
34,880 |
|
||||
Other operating expenses |
|
112,137 |
|
|
104,048 |
|
|
322,900 |
|
|
290,798 |
|
||||
Income from provider relief fund |
|
— |
|
|
(4,442 |
) |
|
— |
|
|
(4,442 |
) |
||||
Depreciation and amortization |
|
37,641 |
|
|
33,388 |
|
|
110,054 |
|
|
96,969 |
|
||||
Interest expense, net |
|
29,924 |
|
|
20,742 |
|
|
86,297 |
|
|
61,651 |
|
||||
Legal settlements expense |
|
— |
|
|
394,181 |
|
|
— |
|
|
394,181 |
|
||||
Loss on impairment |
|
10,459 |
|
|
— |
|
|
11,459 |
|
|
8,694 |
|
||||
Transaction, legal and other costs |
|
8,249 |
|
|
11,247 |
|
|
17,187 |
|
|
26,792 |
|
||||
Total expenses |
|
717,067 |
|
|
1,037,732 |
|
|
2,075,854 |
|
|
2,291,263 |
|
||||
Income (loss) before income taxes |
|
98,567 |
|
|
(287,398 |
) |
|
303,871 |
|
|
(105,325 |
) |
||||
Provision for (benefit from) income taxes |
|
27,199 |
|
|
(71,873 |
) |
|
72,916 |
|
|
(29,907 |
) |
||||
Net income (loss) |
|
71,368 |
|
|
(215,525 |
) |
|
230,955 |
|
|
(75,418 |
) |
||||
Net income attributable to noncontrolling interests |
|
(3,236 |
) |
|
(2,185 |
) |
|
(7,958 |
) |
|
(3,978 |
) |
||||
Net income (loss) attributable to Acadia Healthcare Company, Inc. | $ |
68,132 |
|
$ |
(217,710 |
) |
$ |
222,997 |
|
$ |
(79,396 |
) |
||||
Earnings (loss) per share attributable to Acadia Healthcare Company, Inc. stockholders: | ||||||||||||||||
Basic | $ |
0.74 |
|
$ |
(2.39 |
) |
$ |
2.44 |
|
$ |
(0.87 |
) |
||||
Diluted | $ |
0.74 |
|
$ |
(2.39 |
) |
$ |
2.42 |
|
$ |
(0.87 |
) |
||||
Weighted-average shares outstanding: | ||||||||||||||||
Basic |
|
91,720 |
|
|
91,168 |
|
|
91,571 |
|
|
90,852 |
|
||||
Diluted |
|
92,188 |
|
|
91,168 |
|
|
92,119 |
|
|
90,852 |
|
Acadia Healthcare Company, Inc. |
||||||
Condensed Consolidated Balance Sheets |
||||||
(Unaudited) |
||||||
September 30, |
|
December 31, |
||||
2024 |
|
2023 |
||||
(In thousands) |
||||||
ASSETS | ||||||
Current assets: | ||||||
Cash and cash equivalents | $ |
82,145 |
$ |
100,073 |
||
Accounts receivable, net |
|
383,945 |
|
361,451 |
||
Other current assets |
|
185,972 |
|
134,476 |
||
Total current assets |
|
652,062 |
|
596,000 |
||
Property and equipment, net |
|
2,679,807 |
|
2,266,610 |
||
Goodwill |
|
2,264,851 |
|
2,225,962 |
||
Intangible assets, net |
|
73,139 |
|
73,278 |
||
Deferred tax assets |
|
2,706 |
|
6,658 |
||
Operating lease right-of-use assets |
|
122,771 |
|
117,780 |
||
Other assets |
|
75,121 |
|
72,553 |
||
Total assets | $ |
5,870,457 |
$ |
5,358,841 |
||
LIABILITIES AND EQUITY | ||||||
Current liabilities: | ||||||
Current portion of long-term debt | $ |
71,694 |
$ |
29,219 |
||
Accounts payable |
|
201,379 |
|
156,132 |
||
Accrued salaries and benefits |
|
141,470 |
|
141,901 |
||
Current portion of operating lease liabilities |
|
27,175 |
|
26,268 |
||
Other accrued liabilities |
|
167,782 |
|
532,261 |
||
Total current liabilities |
|
609,500 |
|
885,781 |
||
Long-term debt |
|
1,804,825 |
|
1,342,548 |
||
Deferred tax liabilities |
|
54,112 |
|
1,931 |
||
Operating lease liabilities |
|
105,437 |
|
100,808 |
||
Other liabilities |
|
150,544 |
|
140,113 |
||
Total liabilities |
|
2,724,418 |
|
2,471,181 |
||
Redeemable noncontrolling interests |
|
114,521 |
|
105,686 |
||
Equity: | ||||||
Common stock |
|
918 |
|
913 |
||
Additional paid-in capital |
|
2,675,882 |
|
2,649,340 |
||
Retained earnings |
|
354,718 |
|
131,721 |
||
Total equity |
|
3,031,518 |
|
2,781,974 |
||
Total liabilities and equity | $ |
5,870,457 |
$ |
5,358,841 |
Acadia Healthcare Company, Inc. |
||||||||
Condensed Consolidated Statements of Cash Flows |
||||||||
(Unaudited) |
||||||||
Nine Months Ended September 30, |
||||||||
|
2024 |
|
|
|
2023 |
|
||
(In thousands) |
||||||||
Operating activities: | ||||||||
Net income (loss) | $ |
230,955 |
|
$ |
(75,418 |
) |
||
Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||||||||
Depreciation and amortization |
|
110,054 |
|
|
96,969 |
|
||
Amortization of debt issuance costs |
|
3,061 |
|
|
2,485 |
|
||
Equity-based compensation expense |
|
27,014 |
|
|
23,140 |
|
||
Deferred income taxes |
|
56,133 |
|
|
(21,655 |
) |
||
Legal settlements expense |
|
— |
|
|
394,181 |
|
||
Loss on impairment |
|
11,459 |
|
|
8,694 |
|
||
Other |
|
(3,988 |
) |
|
1,423 |
|
||
Change in operating assets and liabilities, net of effect of acquisitions: | ||||||||
Accounts receivable, net |
|
(20,936 |
) |
|
(40,227 |
) |
||
Other current assets |
|
(3,334 |
) |
|
(77,165 |
) |
||
Other assets |
|
676 |
|
|
309 |
|
||
Accounts payable and other accrued liabilities |
|
(404,942 |
) |
|
23,057 |
|
||
Accrued salaries and benefits |
|
(1,841 |
) |
|
(3,038 |
) |
||
Other liabilities |
|
8,681 |
|
|
17,723 |
|
||
Government relief funds |
|
— |
|
|
(4,442 |
) |
||
Net cash provided by operating activities |
|
12,992 |
|
|
346,036 |
|
||
Investing activities: | ||||||||
Cash paid for acquisitions, net of cash acquired |
|
(53,550 |
) |
|
(349 |
) |
||
Cash paid for capital expenditures |
|
(486,891 |
) |
|
(285,410 |
) |
||
Proceeds from sale of property and equipment |
|
10,227 |
|
|
633 |
|
||
Other |
|
(2,935 |
) |
|
(1,925 |
) |
||
Net cash used in investing activities |
|
(533,149 |
) |
|
(287,051 |
) |
||
Financing activities: | ||||||||
Borrowings on long-term debt |
|
350,000 |
|
|
— |
|
||
Borrowings on revolving credit facility |
|
210,000 |
|
|
40,000 |
|
||
Principal payments on revolving credit facility |
|
(15,000 |
) |
|
(35,000 |
) |
||
Principal payments on long-term debt |
|
(40,968 |
) |
|
(15,938 |
) |
||
Payment of debt issuance costs |
|
(1,518 |
) |
|
— |
|
||
Repurchase of shares for payroll tax withholding, net of proceeds from stock option exercises |
|
(824 |
) |
|
(45,193 |
) |
||
Contributions from noncontrolling partners in joint ventures |
|
3,500 |
|
|
2,538 |
|
||
Distributions to noncontrolling partners in joint ventures |
|
(2,972 |
) |
|
(3,480 |
) |
||
Other |
|
11 |
|
|
30 |
|
||
Net cash provided by (used in) financing activities |
|
502,229 |
|
|
(57,043 |
) |
||
Net (decrease) increase in cash and cash equivalents |
|
(17,928 |
) |
|
1,942 |
|
||
Cash and cash equivalents at beginning of the period |
|
100,073 |
|
|
97,649 |
|
||
Cash and cash equivalents at end of the period | $ |
82,145 |
|
$ |
99,591 |
|
||
$ |
- |
|
$ |
- |
|
|||
Effect of acquisitions: | ||||||||
Assets acquired, excluding cash | $ |
59,235 |
|
$ |
6,766 |
|
||
Liabilities assumed |
|
(4,185 |
) |
|
(128 |
) |
||
Contingent consideration issued in connection with an acquisition |
|
(1,500 |
) |
|
— |
|
||
Redeemable noncontrolling interest resulting from an acquisition |
|
— |
|
|
(6,289 |
) |
||
Cash paid for acquisitions, net of cash acquired | $ |
53,550 |
|
$ |
349 |
|
Acadia Healthcare Company, Inc. |
|||||||||||||||||||||
Operating Statistics |
|||||||||||||||||||||
(Unaudited, Revenue in thousands) |
|||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
||||||||||||||||||
|
|
2024 |
|
|
|
2023 |
|
|
% Change |
|
|
2024 |
|
|
|
2023 |
|
|
% Change |
||
Same Facility Results (1) | |||||||||||||||||||||
Revenue | $ |
802,555 |
|
$ |
739,335 |
|
8.6 |
% |
$ |
2,334,956 |
|
$ |
2,148,408 |
|
8.7 |
% |
|||||
Patient Days |
|
800,880 |
|
|
764,703 |
|
4.7 |
% |
|
2,332,369 |
|
|
2,260,513 |
|
3.2 |
% |
|||||
Admissions |
|
50,368 |
|
|
49,397 |
|
2.0 |
% |
|
147,617 |
|
|
147,130 |
|
0.3 |
% |
|||||
Average Length of Stay (2) |
|
15.9 |
|
|
15.5 |
|
2.7 |
% |
|
15.8 |
|
|
15.4 |
|
2.8 |
% |
|||||
Revenue per Patient Day | $ |
1,002 |
|
$ |
967 |
|
3.6 |
% |
$ |
1,001 |
|
$ |
950 |
|
5.3 |
% |
|||||
Adjusted EBITDA margin (3) |
|
29.7 |
% |
|
29.3 |
% |
40 bps |
|
29.3 |
% |
|
28.8 |
% |
50 bps | |||||||
Adjusted EBITDA margin excluding income from provider relief fund |
|
29.7 |
% |
|
28.7 |
% |
100 bps |
|
29.3 |
% |
|
28.6 |
% |
70 bps | |||||||
Facility Results | |||||||||||||||||||||
Revenue | $ |
815,634 |
|
$ |
750,334 |
|
8.7 |
% |
$ |
2,379,725 |
|
$ |
2,185,938 |
|
8.9 |
% |
|||||
Patient Days |
|
815,126 |
|
|
779,296 |
|
4.6 |
% |
|
2,375,477 |
|
|
2,306,109 |
|
3.0 |
% |
|||||
Admissions |
|
51,513 |
|
|
50,302 |
|
2.4 |
% |
|
151,082 |
|
|
150,237 |
|
0.6 |
% |
|||||
Average Length of Stay (2) |
|
15.8 |
|
|
15.5 |
|
2.1 |
% |
|
15.7 |
|
|
15.3 |
|
2.4 |
% |
|||||
Revenue per Patient Day | $ |
1,001 |
|
$ |
963 |
|
3.9 |
% |
$ |
1,002 |
|
$ |
948 |
|
5.7 |
% |
|||||
Adjusted EBITDA margin (3) |
|
28.2 |
% |
|
28.7 |
% |
-50 bps |
|
27.9 |
% |
|
28.0 |
% |
-10 bps | |||||||
Adjusted EBITDA margin excluding income from provider relief fund |
|
28.2 |
% |
|
28.1 |
% |
10 bps |
|
27.9 |
% |
|
27.8 |
% |
10 bps | |||||||
(1) Same facility results for the periods presented include facilities we have operated for more than one year and exclude certain closed services. | |||||||||||||||||||||
(2) Average length of stay is defined as patient days divided by admissions. | |||||||||||||||||||||
(3) For each of the three and nine months ended September 30, 2023, includes income from provider relief fund of |
Acadia Healthcare Company, Inc. |
|||||||||||||||
Reconciliation of Net Income Attributable to Acadia Healthcare Company, Inc. to Adjusted EBITDA |
|||||||||||||||
(Unaudited) |
|||||||||||||||
|
|
|
|
|
|
|
|
||||||||
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
||||||||||||
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
|
(in thousands) |
||||||||||||||
Net income (loss) attributable to Acadia Healthcare Company, Inc. | $ |
68,132 |
|
$ |
(217,710 |
) |
$ |
222,997 |
|
$ |
(79,396 |
) |
|||
Net income attributable to noncontrolling interests |
|
3,236 |
|
|
2,185 |
|
|
7,958 |
|
|
3,978 |
|
|||
Provision for (benefit from) income taxes |
|
27,199 |
|
|
(71,873 |
) |
|
72,916 |
|
|
(29,907 |
) |
|||
Interest expense, net |
|
29,924 |
|
|
20,742 |
|
|
86,297 |
|
|
61,651 |
|
|||
Depreciation and amortization |
|
37,641 |
|
|
33,388 |
|
|
110,054 |
|
|
96,969 |
|
|||
EBITDA |
|
166,132 |
|
|
(233,268 |
) |
|
500,222 |
|
|
53,295 |
|
|||
Adjustments: | |||||||||||||||
Equity-based compensation expense (a) |
|
9,467 |
|
|
8,163 |
|
|
27,014 |
|
|
23,140 |
|
|||
Transaction, legal and other costs (b) |
|
8,249 |
|
|
11,247 |
|
|
17,187 |
|
|
26,792 |
|
|||
Legal settlements expense (c) |
|
— |
|
|
394,181 |
|
|
— |
|
|
394,181 |
|
|||
Loss on impairment (d) |
|
10,459 |
|
|
— |
|
|
11,459 |
|
|
8,694 |
|
|||
Adjusted EBITDA | $ |
194,307 |
|
$ |
180,323 |
|
$ |
555,882 |
|
$ |
506,102 |
|
|||
Adjusted EBITDA margin |
|
23.8 |
% |
|
24.0 |
% |
|
23.4 |
% |
|
23.2 |
% |
|||
Income from provider relief fund |
|
— |
|
|
(4,442 |
) |
|
— |
|
|
(4,442 |
) |
|||
Adjusted EBITDA excluding income from provider relief fund | $ |
194,307 |
|
$ |
175,881 |
|
$ |
555,882 |
|
$ |
501,660 |
|
|||
Adjusted EBITDA margin excluding income from provider relief fund |
|
23.8 |
% |
|
23.4 |
% |
|
23.4 |
% |
|
22.9 |
% |
|||
See footnotes on page 10. |
Acadia Healthcare Company, Inc. |
||||||||||||||
Reconciliation of Net Income Attributable to Acadia Healthcare Company, Inc. to |
||||||||||||||
Adjusted Income Attributable to Acadia Healthcare Company, Inc. |
||||||||||||||
(Unaudited) |
||||||||||||||
|
|
|
|
|
|
|
|
|
||||||
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
||||||||||
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||
|
|
(in thousands, except per share amounts) |
||||||||||||
Net income (loss) attributable to Acadia Healthcare Company, Inc. | $ |
68,132 |
$ |
(217,710 |
) |
$ |
222,997 |
$ |
(79,396 |
) |
||||
Adjustments to income: | ||||||||||||||
Transaction, legal and other costs (b) |
|
8,249 |
|
11,247 |
|
|
17,187 |
|
26,792 |
|
||||
Legal settlements expense (c) |
|
— |
|
394,181 |
|
|
— |
|
394,181 |
|
||||
Loss on impairment (d) |
|
10,459 |
|
— |
|
|
11,459 |
|
8,694 |
|
||||
Provision for (benefit from) income taxes |
|
27,199 |
|
(71,873 |
) |
|
72,916 |
|
(29,907 |
) |
||||
Adjusted income before income taxes attributable to Acadia Healthcare Company, Inc. |
|
114,039 |
|
115,845 |
|
|
324,559 |
|
320,364 |
|
||||
Income tax effect of adjustments to income (e) |
|
29,960 |
|
28,756 |
|
|
79,614 |
|
79,947 |
|
||||
Adjusted income attributable to Acadia Healthcare Company, Inc. |
|
84,079 |
|
87,089 |
|
|
244,945 |
|
240,417 |
|
||||
Income from provider relief fund, net of taxes |
|
— |
|
(3,237 |
) |
|
— |
|
(3,237 |
) |
||||
Adjusted income attributable to Acadia Healthcare Company, Inc. excluding income from provider relief fund | $ |
84,079 |
$ |
83,852 |
|
$ |
244,945 |
$ |
237,180 |
|
||||
Weighted-average shares outstanding - diluted (f) |
|
92,188 |
|
91,655 |
|
|
92,119 |
|
91,684 |
|
||||
Adjusted income attributable to Acadia Healthcare Company, Inc. per diluted share | $ |
0.91 |
$ |
0.95 |
|
$ |
2.66 |
$ |
2.62 |
|
||||
Income from provider relief fund, net of taxes, per diluted share |
|
— |
|
(0.04 |
) |
|
— |
|
(0.04 |
) |
||||
Adjusted income attributable to Acadia Healthcare Company, Inc., excluding income from provider relief fund, per diluted share | $ |
0.91 |
$ |
0.91 |
|
$ |
2.66 |
$ |
2.58 |
|
||||
See footnotes on page 10. |
Acadia Healthcare Company, Inc. |
Footnotes |
We have included certain financial measures in this press release, including those listed below, which are “non-GAAP financial measures” as defined under the rules and regulations promulgated by the SEC. These non-GAAP financial measures include, and are defined, as follows: |
• EBITDA: net income (loss) attributable to Acadia Healthcare Company, Inc. adjusted for net income attributable to noncontrolling interests, provision for (benefit from) income taxes, net interest expense and depreciation and amortization. |
• Adjusted EBITDA: EBITDA adjusted for equity-based compensation expense, transaction, legal and other costs, legal settlements expense and loss on impairment. |
• Adjusted EBITDA excluding income from provider relief fund: Adjusted EBITDA adjusted for income from provider relief fund. |
• Adjusted EBITDA margin: Adjusted EBITDA divided by revenue. |
• Adjusted EBITDA margin excluding income from provider relief fund: Adjusted EBITDA excluding income from provider relief fund divided by revenue. |
• Adjusted income before income taxes attributable to Acadia Healthcare Company, Inc.: net income (loss) attributable to Acadia Healthcare Company, Inc. adjusted for transaction, legal and other costs, legal settlements expense, loss on impairment and provision for (benefit from) income taxes. |
• Adjusted income attributable to Acadia Healthcare Company, Inc.: Adjusted income before income taxes attributable to Acadia Healthcare Company, Inc. adjusted for the income tax effect of adjustments to income. |
• Adjusted income attributable to Acadia Healthcare Company, Inc. excluding income from provider relief fund: Adjusted income attributable to Acadia Healthcare Company, Inc. adjusted for income from provider relief fund. |
• Net leverage ratio: Long-term debt (excluding |
The non-GAAP financial measures presented herein are supplemental measures of our performance and are not required by, or presented in accordance with, generally accepted accounting principles in |
The Company is not able to provide a reconciliation of projected Adjusted EBITDA and adjusted earnings per diluted share, where provided, to expected results due to the unknown effect, timing and potential significance of transaction-related expenses and the tax effect of such expenses. |
(a) Represents the equity-based compensation expense of Acadia. |
(b) Represents transaction, legal and other costs incurred by Acadia primarily related to legal, government investigations, management transition, termination, restructuring, acquisition and other similar costs. |
(c) Represents legal settlements expense related to the Desert Hills litigation. |
(d) Represents non-cash impairment charges related to the closure of certain facilities. |
(e) Represents the income tax effect of adjustments to income based on tax rates of |
(f) For the three and nine months ended September 30, 2023, approximately 0.5 million and 0.8 million outstanding shares of restricted stock and shares of common stock issuable upon exercise of outstanding stock option awards, respectively, have been included in the calculation of weighted-average shares outstanding-diluted. These shares are excluded from the calculation of diluted earnings per share in the condensed consolidated statement of operations because the net loss for the three and nine months ended September 30, 2023 causes such securities to be anti-dilutive. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20241030593005/en/
Investor Contact:
Patrick Feeley
Senior Vice President, Investor Relations
(615) 861-6000
Source: Acadia Healthcare Company, Inc.
FAQ
What was Acadia Healthcare's (ACHC) revenue in Q3 2024?
How many CTCs does Acadia Healthcare (ACHC) operate as of Q3 2024?
What is Acadia Healthcare's (ACHC) updated revenue guidance for 2024?